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Background
Co-infection with Hepatitis C has been associated with
higher rates of treatment failure in cohort studies.
Methods
256 patients with HIV RNA <50 on current HAART for
over 24 weeks (NNRTI based (43%), or PI based (57%),
switched to DRV/r 800/100 mg once daily, either as
monotherapy (n = 127) or with 2NRTI (triple therapy
arm, n = 129). This sub-analysis investigated the effect
of Hepatitis C co-infection on HIV RNA levels during
the trial.
Results
At baseline, more patients were HCV antibody positive
by serology in the DRV/r arm (17%) than in the control
arm (9%). In the primary efficacy analysis at Week 48,
86.2% of patients in the monotherapy arm and 87.8% in
the triple therapy arm had HIV RNA <50 copies/mL.
Only four of the confirmed elevations in HIV RNA were
above 400 copies/mL (two in each arm). In multivariate
analysis (Per Protocol), hepatitis C co-infection was a
significant predictor of confirmed HIV RNA elevations
(p < 0.01). For patients infected only with HIV (HCV
antibody negative at baseline), the percent HIV RNA
<50 was 88.1% in the monotherapy arm versus 87.3% in
the triple therapy arm. For patients HCV antibody posi-
tive at baseline, the percent HIV RNA <50 was 61.9%
for the monotherapy arm versus 58.3% for the triple
therapy arm. Three patients had acute HCV infection
during the trial (all in the DRV/r arm): all three had
HIV RNA elevations at the time of acute HCV infection.
Discussion
In this study for patients with HIV RNA <50 copies/mL
at screening, switching to DRV/r monotherapy showed
non-inferior efficacy versus 2NRTI + DRV/r. Hepatitis
C co-infection was more prevalent in the DRV/r mono-
therapy arm, and was a significant, independent predic-
tor of transient, low-level HIV RNA viraemia. Hepatitis
C co-infection might be a marker of poor adherence, or
might be directly correlated with HIV RNA viraemia.
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